ArticlePloS one2025
Antibiofilm effects of bacteriocin PCM7-4 on Listeria monocytogenes.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing Probiotic LAB and Bacteriocins for Clean-Label Food Processing and Biopreservation: Omics, Molecular Innovations and Industrial Applications.Probiotics and antimicrobial proteins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Listeria monocytogenes is a significant zoonotic pathogen capable of forming biofilms on food and other materials, representing a considerable risk to human health and animal husbandry. The use of bacteriocins as potential new antibacterial and antibiofilm reagents has attracted considerable interest. This study aimed to determine the inhibitory effects of bacteriocin PCM7-4 on L. monocytogenes biofilm formation. In this study, bacteriocin PCM7-4 of SICs (1/16 × MIC, 1/8 × MIC) significantly inhibited the formation of L. monocytogenes biofilm. Bacteriocin PCM7-4 of SICs significantly reduced the production of bacterial extracellular polysaccharides, and could decrease the bacterial motility, meanwhile, PCM7-4 significantly reduced the number and viability of bacteria within the biofilm. RT-qPCR results showed that bacteriocin PCM7-4 significantly reduced the expression of flagella, community sensing and virulence factor genes associated with biofilm formation. The results demonstrated the considerable potential of bacteriocin PCM7-4 as a therapeutic agent for the prevention and treatment of L. monocytogenes biofilms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.